TRIUMPH-4 Retatrutide Trial Design 2026

Posted on by Kate Cai

TRIUMPH-4 Trial Design & What We Know About Retatrutide (2026)

Status note (September 4, 2026): The TRIUMPH-4 Phase 3 retatrutide trial is ongoing. As of this update only the protocol/design paper has been published (DOM, Jan 2026, PMID 41090431). The peer-reviewed efficacy data referenced throughout this post is the published Phase 2 Jastreboff et al. NEJM 2023 trial (PMID 37366315). Any “TRIUMPH-4 Phase 3 outcome” figure circulating in third-party blog content is currently UNVERIFIED — Phase 3 readout pending.

Research Highlights

  • Published Phase 2 data (Jastreboff 2023, PMID 37366315): Body-weight reduction at 48 weeks at the highest tolerated dose (12 mg weekly); ~338 participants; double-blind RCT.
  • TRIUMPH-4 Phase 3 status: Topline results reported. On December 11, 2025 Lilly announced topline TRIUMPH-4 results in adults with obesity or overweight and knee osteoarthritis at 68 weeks (Lilly investor release); Lilly states the detailed results will be presented at a medical meeting and published in a peer-reviewed journal. The trial-design paper is published (DOM Jan 2026, PMID 41090431); as of August 29, 2026 no TRIUMPH-4 results paper was indexed in PubMed. The first peer-reviewed retatrutide Phase 3 paper is TRANSCEND-T2D-1, in type 2 diabetes, published in The Lancet on June 13, 2026 (PMID 42250575).
  • Mechanism (validated by Phase 2 work): Retatrutide co-activates GLP-1, GIP, and glucagon receptors. The triple-receptor design produced the largest effect size in the GLP-1-family Phase 2 literature.

Why TRIUMPH-4 Matters

TRIUMPH-4 is the Phase 3 program designed to confirm and extend the Phase 2 efficacy of retatrutide — the first triple-receptor (GLP-1 / GIP / glucagon) agonist to advance into late-stage clinical research. The Phase 2 data published by Jastreboff et al. in NEJM (2023) established a striking effect-size signal at the 12 mg weekly dose, with a clear concentration-response curve and a manageable safety profile dominated by GI adverse events.

Phase 3 confirmation matters because Phase 2 trials enroll smaller populations under tightly controlled conditions. Phase 3 tests whether the same mechanism produces durable, reproducible, and safe effects in larger and more diverse research populations — and it is the regulatory threshold for eventual therapeutic indications.

What Phase 2 Actually Showed (Jastreboff et al., NEJM 2023)

The Phase 2 trial is the basis for everything currently known about retatrutide efficacy. Key features:

Aspect Detail
Phase 2
Trial reference Jastreboff AM et al., NEJM 2023 (PMID 37366315)
Sample size ~338 participants
Population Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with ≥1 weight-related comorbidity
Trial arms Four retatrutide arms vs. placebo, as published (Jastreboff 2023, PMID 37366315)
Duration 48 weeks
Primary endpoint Percent change in body weight from baseline
Headline efficacy Up to ~24.2% mean reduction at 48 weeks (12 mg)
Safety profile GI adverse events dominated; serious AEs uncommon

The Phase 2 trial’s central finding was a clear dose-response gradient and a triple-mechanism effect size that exceeded published dual-agonist (tirzepatide) baselines in non-head-to-head comparison.

TRIUMPH-4 Phase 3: What We Know From the Protocol

The TRIUMPH-4 protocol paper (DOM, Jan 2026, PMID 41090431) describes the Phase 3 design:

  • Status: Ongoing — efficacy results not yet published
  • Design: Multi-arm, double-blind, randomized controlled Phase 3 trial of retatrutide vs. placebo (and active comparators in companion TRIUMPH-family trials) in adults with obesity
  • Primary endpoint: Change in body weight from baseline at the trial endpoint
  • Population: Adults with obesity / overweight + comorbidities (refer to ClinicalTrials.gov for current enrollment criteria)

Until the Phase 3 efficacy readout is peer-reviewed, no specific TRIUMPH-4 weight-loss percentage should be cited. The figures circulating in third-party content (including in some research-peptide vendor blogs through Q1 2026) appear to have been fabricated and should be treated as unverified.

What Phase 2 Implied About the Mechanism

The Phase 2 trial is informative for mechanism research even though we await Phase 3 confirmation. Three points emerge:

  1. Triple agonism produced a steep concentration-response curve. Effect size scaled monotonically with retatrutide concentration up to the 12 mg dose, suggesting genuine triple-receptor synergy rather than receptor saturation.
  2. GI tolerability was the dominant safety signal. GI adverse events were frequent at higher doses, consistent with the glucagon-receptor contribution to GI motility. Discontinuation rates were elevated relative to dual-agonist references.
  3. Body composition trended toward favorable adipose-vs-lean ratio. Phase 2 imaging substudies supported the interpretation that the weight loss was predominantly fat mass.

These signals frame the questions Phase 3 will answer: do they replicate in a larger population over a longer duration with better-characterized safety endpoints?

TRIUMPH-4 vs. SURMOUNT-1: What the Comparison Currently Supports

Direct apples-to-apples comparison of TRIUMPH-4 vs. SURMOUNT-1 is not yet possible because TRIUMPH-4 Phase 3 outcomes are unpublished. The currently defensible comparison is Phase 2 retatrutide vs. Phase 3 tirzepatide (SURMOUNT-1):

Metric Retatrutide Phase 2 (Jastreboff 2023, 12 mg) Tirzepatide SURMOUNT-1 (15 mg)
Trial Phase 2 3
Sample Size ~338 ~2,539
Endpoint Duration 48 weeks 72 weeks
GI Burden Higher than dual-agonist baseline ~37% nausea incidence
Mechanism GLP-1 + GIP + glucagon GLP-1 + GIP

The Phase 2 retatrutide data is encouraging but cross-phase comparisons are limited. The TRIUMPH-4 Phase 3 readout, when published, will provide the appropriate same-phase comparator.

Why “Triple Agonism” is Mechanistically Different

Phase 2 evidence supports — but does not yet definitively confirm — that triple-receptor agonism is mechanistically distinct from dual-agonism, not just incrementally additive:

  • GLP-1 receptor: Appetite suppression via hypothalamic signaling, glucose-dependent insulin release, delayed gastric emptying.
  • GIP receptor: Insulin amplification, modulation of postprandial lipid dynamics, possible visceral-fat-specific effects.
  • Glucagon receptor: Hepatic glucose mobilization, lipolytic / β-oxidation upregulation, thermogenic energy expenditure.

The glucagon arm contributes increased energy expenditure on top of GLP-1’s appetite suppression — a mechanism the dual-agonist (tirzepatide) does not engage. This is the theoretical basis for the larger effect size and explains why GI burden is higher (glucagon-receptor activation has known GI motility effects).

What This Means for Researchers Today

For researchers planning retatrutide protocol work in 2026:

  1. Cite Phase 2 for currently-defensible retatrutide outcomes (Jastreboff 2023, PMID 37366315).
  2. Cite the Phase 3 protocol (DOM 2026, PMID 41090431) for trial design — do not cite Phase 3 efficacy yet.
  3. Watch for the Phase 3 readout through ClinicalTrials.gov and NEJM / Lancet.
  4. Characterise the material in front of you before you use it — by HPLC and mass spectrometry, at a lab that has no relationship to whoever sold it. Re-testing surveys published in 2025–2026 found roughly 47% of sampled research-market retatrutide did not match its label. That figure is about the market, not about any one seller, and it is the reason the characterisation step is not optional. See our retatrutide quality crisis report.
  5. Anchor any claim to the Phase 2 publication rather than to a speculative Phase 3 figure — the published record is the only defensible source.

Common Questions

Q: What is the published TRIUMPH-4 efficacy result? There is no published TRIUMPH-4 Phase 3 efficacy result as of May 2026. Only the protocol paper (DOM Jan 2026, PMID 41090431) is published. The relevant peer-reviewed retatrutide efficacy data is the Phase 2 Jastreboff et al. NEJM 2023 paper (PMID 37366315).

Q: What about the 23.7% or 28.7% figures circulating online? Those figures appear in third-party content (including some research-peptide vendor blogs in Q1 2026) but are unverified against any published Phase 3 publication. Treat them as fabricated until a peer-reviewed Phase 3 readout publishes.

Q: When will Phase 3 results publish? Watch ClinicalTrials.gov, NEJM, and Lancet. Phase 3 weight-loss trial readouts typically publish 6–18 months after primary endpoint completion. Until then, cite Phase 2.

Q: Is retatrutide still worth researching ahead of Phase 3? Yes — the Phase 2 effect size and the mechanism rationale are why the compound remains scientifically interesting. Mechanism studies, comparative pharmacology, in vitro receptor work and in vivo animal model research are all served by the published Phase 2 record. None of that turns research-market material into the compound the trials used.

Q: How does the retatrutide quality crisis interact with this? It is the reason the trial results cannot be read across to anything else. The Lilly trials were run on material the sponsor made and controlled for its own clinical programme, under its own manufacturing and release process. Research-market retatrutide is a different supply chain entirely — re-testing surveys published in 2025–2026 found roughly 47% of sampled material did not match its label. Those are two separate things. A published trial outcome describes the sponsor’s material and the sponsor’s trial; it says nothing about any other vial, ours included. Anything intended as replication work has to be characterised on its own, by HPLC and mass spectrometry, before the work starts. See our retatrutide quality crisis report.

Q: What is the safety signal we should pay attention to? GI tolerability dominates the Phase 2 safety profile, with higher rates than dual-agonist comparators. Pancreatitis, gallstone, and cardiovascular signals from Phase 2 were not statistically meaningful but warrant continued monitoring in Phase 3 and post-marketing settings.

Verified References

Canonical, WebFetch-verified PMIDs / DOIs are consolidated in Product Catalog/MASTER_RESEARCH_CITATIONS.md. Two anchor references for this post:

  • Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. NEJM 2023. PMID: 37366315. (Verified — see MASTER_RESEARCH_CITATIONS.md.)
  • TRIUMPH-4 protocol paper. Diabetes Obesity & Metabolism, January 2026. PMID: 41090431. Phase 3 trial design; efficacy results pending.

Any other PMID or DOI in this category must be WebFetch-verified before citation.

Last updated: September 4, 2026 (May 20, 2026: rewritten to remove unverified Phase 3 efficacy figures). For research purposes only. Not for human consumption. These statements have not been evaluated by the FDA.

Kate Cai